: Coronavirus cause severe harm to the health of both humans as well as animals, creating a major global health problem affecting millions of populations. Considering situational emergency of identifying novel targeted therapy, we have chosen herbal compound Adathoda justice/ vasica which is high potent olden vital compound having key role in various respiratory conditions with multiple beneficial uses. Adathoda is promoted and supported by the Ministry of AYUSH for symptomatic management of respiratory ailments in case of COVID 19. In this study, we focused Adathoda primary active alkaloid vasicine efficacy against coronavirus infectious symptoms, evaluated by in Silico screening studies on virus proteins ACE 2 Receptor, 3CL protease and Spike protein SARS HR1 motif using PyRx tool and AutoDoc 1.5.6. Based on PyRx results, Vasicine with ACE 2 Receptor shown higher docking affinity score -7.1 K/cal respectively when compared to other virus proteins. AutoDoc 1.5.6 screening study report showed that vasicine promotes good inhibitory constant 486.54 mM on 3CL protease more than others. Results reveal that the vasicine could be a potential target for the treatment of COVID 19. This study adds strong evidence to the claim by the advisory released by AYUSH. Based on the results with available literature Adathoda could be a drug helpful in relieving symptoms in non COVID cases those who were quarantined or in lockdown pace thereby reducing pandemic panic and in confirmed asymptomatic or mild cases. For usage in moderate to severe cases this could be an add on therapy with existing modern medical therapy.
Background: In COVID-19, the respiratory tract is usually affected by SARS-CoV-2 infection. Due to viral transmission in the blood and an overwhelming inflammatory response, including cytokine storm, the condition can progress to acute respiratory distress syndrome and failure. Methylene blue is the only medicine that has been shown to reduce the excessive generation of reactive species and cytokines. Case Presentation: A 51-year-old male patient came to the hospital with shortness of breath. On room air the patient was having 70% Spo2. The patient was treated with noninvasive ventilator (NIV) and Standard of care (SOC). Due to prolonged hypoxia and respiratory distress, the patient was treated with NIV and the methylene blue (MB) was given in a humidifier for 5 days. Result: Methylene blue resulted in a significant decrease in respiratory distress and a steep rise in Spo2. Conclusion: We suggest trying methylene blue as an additional intervention in COVID-related acute respiratory distress, to avoid the disease's devastating consequences.
Introduction: Pleural effusions can be caused by several conditions such as cancer, connective tissue disease, and infection. They are occasionally caused due to the drug as an adverse reaction. Most commonly systemic minoxidil use can cause pleural effusions in patients with chronic kidney disease. Case presentation: We present a case of a patient without chronic kidney disease who developed pleural effusion as a result of unintentional use of topical minoxidil orally. The patient's oxygen saturation was 90% on room air, there was dullness to percussion and asymmetrical chest expansion with diminished air entry on both sides. In chest x-ray there was bilateral pleural opacities. In ultrasonography of the chest, it was showed minimal pleural effusions. The patient was managed with diuretics and airway management which resolved completely. Conclusion: Minoxidil is a commonly used drug by many people for the treatment of hair fall with or without doctor advice. We would like to stress that even though rare, physicians/pulmonologists should be aware of its rare side effects of topical minoxidil, and it should be kept in mind as a differential diagnosis for pleural effusion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.